Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Mindstate Design Labs AI-Designed Trial Gets FDA Approval
Mindstate Design Labs gains FDA and EMA approval for human trials of MSD-001, a neurotech AI-designed compound targeting specific serotonin receptors. The Phase 1 trials, to be held in Leiden, will assess safety and neural impacts using advanced techniques. Mindstate's Osmanthus platform integrates AI with 70,000 drug reports and biochemical data to design precise psychoactive effects.
Psychedelic drugs and treating mental illness
Researchers believe psychedelics could treat mental health, with ongoing trials in UK and worldwide. Psilocybin shows most evidence for effectiveness, with potential benefits beyond serious conditions. Despite tight UK control, businesses invest in psychedelic treatments, anticipating global authorization.
Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
Psilera's PSIL-006, a non-psychedelic psilocybin-based drug, shows promise in treating frontotemporal dementia (FTD) with a strong safety profile in preclinical studies, potentially paving the way for FDA approval and addressing a critical need in dementia care.
FDA Rejection Of MDMA Could Fuel Black Market Demand, Warns CEO Of Women's ...
FDA advisory panel rejected MDMA-assisted therapy for PTSD due to concerns over clinical trial design, potential abuse, and misconduct allegations. April Pride, CEO of SetSet, views this as a setback for psychedelic medicine, advocating for regulatory reforms and harm-reduction education. Despite the rejection, Pride remains optimistic about the future of psychedelic medicine, expecting innovation in safer compounds and protocols.
Recreational drug use tied to repeat cardiovascular events
Recreational drug use triples risk for repeat serious cardiovascular events within one year of hospitalization, according to a study presented at the European Society of Cardiology Congress 2024. The study, involving 1,392 patients, found that 11% tested positive for recreational drugs, with 7% experiencing major adverse cardiovascular and cerebrovascular events (MACCE) at one year, significantly higher among drug users (13% vs. 6%).
Reagan Udall Foundation Facilitates Discussion on Urgent Needs in PTSD Therapy
The Reagan Udall Foundation hosted a meeting on advancing PTSD treatments, highlighting the unmet need and discussing current clinical trials, including those for MDMA-assisted therapy. Participants emphasized the importance of representative clinical trials and the impact of trauma on lives, with some criticizing the FDA's handling of MDMA trials. Despite challenges, there is optimism for future advancements in PTSD treatment.
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent
SciSparc and Clearmind announce an international patent for combining MDMA with N-Acylethanolamines to enhance safety and efficacy in mental health and addiction treatments.
Lykos CEO to Resign After FDA Rejection of MDMA Therapy, Layoffs
Lykos Therapeutics CEO Amy Emerson steps down, interim CEO Michael Mullette appointed. Emerson to remain as senior advisor. Lykos faces FDA rejection for MDMA therapy, plans resubmission. Company also names David Hough as CMO and lays off 75% of workforce.
Lykos CEO to depart after FDA rejection, layoffs
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
'Tofu-Like' Psychedelic Gets FDA Nod - Mindstate's AI-Designed Therapy To Begin Human Trials
Mindstate Design Labs received FDA and EMA approval for human trials of MSD-001, described as 'psychedelic tofu' for its mild effects. The trials aim to validate the neurotech AI platform, Osmanthus, designed to create tailored altered states of consciousness. CEO Dillan DiNardo envisions using psychedelics as tools to understand and design specific mental states, potentially addressing conditions beyond traditional psychedelic uses.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath